Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Published byKornélia Halász Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right."— Presentation transcript:

1 Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin treatment (B), six months after zoledronic acid administration (C), and finally almost 10 years after the infusion (D). The radiotracer uptake increased with calcitonin use, while a single 5 mg zoledronate infusion resulted in rapid and sustained response. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Rheumatology (Oxford), kez070, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.
(A) Calcinosis cutis on the extensor side of the left upper arm ...

(A) Calcinosis cutis on the extensor side of the left upper arm ...
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
(A) Axial ... (A) Axial images showed symmetric, strong high intensity in the connective tissues surrounded by femoral muscles and mild high intensity.

(A) Axial ... (A) Axial images showed symmetric, strong high intensity in the connective tissues surrounded by femoral muscles and mild high intensity.
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.
(A) Pelvic X-ray showing diffuse osteoaddensing ...

(A) Pelvic X-ray showing diffuse osteoaddensing ...
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Similar presentations

Ads by Google